ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints showed improvements in depressive symptoms and sleep. BNC210 was well-tolerated with a safety profile supporting chronic administration. Company plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the registrational path for BNC210 in PTSD. Webcast and conference call was held 28 September 2023 at 8:00 AM EST (10:00 PM AEST). Please click on the link to watch the replay: https://lifescievents.com/event/bnox/ ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 29, 2023 /PRNewswire/ Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced pos
LINCOLNVILLE Lise Becu, Rosey Gerry, and Corinne Gentry will perform Friday, Sept. 29, 2023, from 5 - 7 p.m., at Foda Restaurant, in Appleton. Lise Becu and Rosey Gerry have been performing up and down Midcoast Maine for many years, putting a.
CAMDEN Contemporary folk musicians Jocelyn Pettit and Ellen Gira will perform Friday, Sept. 29, at 7:30 p.m., at the Camden Opera House, 29 Elm St. “This North America-based fiddle and cello duo fuse traditional and contemporary folk music styles.